Adagene Announces Results From Latest Data Cut From Phase 1b/2 Study Of Muzastotug In Patients With Advanced Microsatellite Stable Colorectal Cancer With No Liver Metastases

Adagene Inc. reported a 31% confirmed overall response rate (ORR) for its drug muzastotug at a 20 mg/kg dose in a Phase 1b/2 study, compared to a 13% ORR at 10 mg/kg. The median progression-free survival (PFS) was 6.7 months for the 20 mg/kg cohort, exceeding the 4.8 months observed in the 10 mg/kg cohort. The company noted a low overall discontinuation rate of 4% across 67 patients and no severe treatment-related adverse events. Adagene is currently enrolling patients for a randomized Phase 2 trial, with results anticipated in the first half of 2027.